drugset / Trial / NCT06368726

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

NCT06368726

Phase 1 Enrolling by invitation 180 enrolled Spanish Foundation for Neurometrics Development
RandomizedParallel-groupSingle-blindTreatment

Summary

Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS

Timeline

Start
2024-04-01
Primary completion
2025-12-12
Completion
2026-06-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified